icon

$0 Co-Pay Program

Rubraca is available at $0 co-pay to 100% of commercially insured patients, regardless of income.

Learn more
icon

Text-based support

The Clovis4YOU™ text message support program is a personalized patient program with medication reminders, daily tips, emotional support, and more that can help you throughout treatment.

Learn more
icon

Share Your Story

You can make a difference for yourself and others by sharing your experiences and perspective.

Learn more

Understanding recurrence

Empower yourself with knowledge

Learning your cancer has returned can be overwhelming. But you are brave; and the sooner you address the diagnosis, the sooner you can make significant and positive treatment decisions alongside your healthcare team. Stay involved. Stay informed. Ask every question you might have.
Take role imag

Recurrence is common

Although most ovarian cancers respond well to chemotherapy, it is common for the disease to return. That's why it's important to ask your healthcare team what options you have following chemotherapy. Remember, if you are among the 85% of women who experience a recurrence, you are not alone.

Recurrent ovarian cancer as a chronic disease

Over the last decade, many new drugs and treatments have become available to treat recurrent ovarian cancer. With these advancements, the cancer can often be manageable and thought of as a chronic disease. PARP inhibitors like Rubraca were created to keep fighting the cancer after chemotherapy. Rubraca can be taken orally at home so that you can keep doing the things you love.

Rubraca was created to keep fighting cancer after chemotherapy

Clinical trials studied Rubraca as a maintenance therapy and as an active treatment. The graphic below helps explain the difference.

You have had prior treatments, made many health decisions, and had at least 2 rounds of chemotherapy.

If it is right for you, Rubraca can be used in different ways.

Your doctor tells you you’re having a response to chemotherapy, which means your cancer has stopped growing or is shrinking

Your doctor may recommend more chemotherapy. If you don’t respond and you are BRCA+, your doctor may prescribe Rubraca

If you are BRCA+, your doctor may put you directly on Rubraca

After 2

chemotherapies

Cancer returns

Chemotherapy

Rubraca maintenance

If chemotherapy helped shrink or get rid of your cancer, Rubraca maintenance may help you maintain the benefits of chemotherapy by keeping your cancer from returning or growing for a longer period of time

Rubraca treatment

Rubraca may help shrink (treat) your cancer even if the disease progressed during chemotherapy. Since there may not be any chemotherapy benefits to maintain, this is simply called “treatment”

 
 
 
 
 

You have had prior treatments, made many health decisions, and had at least 2 rounds of chemotherapy. If it is right for you, Rubraca can be used in different ways.

Your doctor tells you you’re having a response to chemotherapy, which means your cancer has stopped growing or is shrinking

Your doctor may recommend more chemotherapy. If you don’t respond and you are BRCA+, your doctor may prescribe Rubraca

If you are BRCA+, your doctor may put you directly on Rubraca

After 2

chemotherapies

After 2

chemotherapies

Cancer returns

Chemotherapy

Rubraca maintenance

If chemotherapy helped shrink or get rid of your cancer, Rubraca maintenance may help you maintain the benefits of chemotherapy by keeping your cancer from returning or growing for a longer period of time

Rubraca treatment

Rubraca may help shrink (treat) your cancer even if the disease progressed during chemotherapy. Since there may not be any chemotherapy benefits to maintain, this is simply called “treatment”

1

2

 
 
 
 
 
Gen image
Understanding genetic mutations
and disease
Learn more

We at Clovis Oncology admire the strength and courage of women living with recurrent ovarian cancer, and extend our sincere gratitude to participants of the Rubraca clinical trials.

What is Rubraca used for?

Rubraca is a prescription medicine used for:

  • The maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy
  • The treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

It is not known if Rubraca is safe and effective in children.

What Warnings should I know about Rubraca?

Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

You should not use Rubraca if:

  • You are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca
    • Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca
    • Talk to your healthcare provider about birth control methods that may be right for you
    • Tell your healthcare provider right away if you become pregnant
  • You are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time

What other important information should I know about Rubraca?

Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

Avoid spending time in sunlight while on Rubraca since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the side effects of Rubraca?

The most common side effects for women in the Rubraca clinical studies were nausea, tiredness/weakness, stomach pain, rash, altered taste, decrease in hemoglobin, abnormal liver or kidney function blood tests, constipation, vomiting, diarrhea, decrease in platelets, upper respiratory tract infection, mouth sores, decreased appetite, shortness of breath, and decrease in white blood cell count.

What other medications might interact with Rubraca?

Rubraca can increase the amounts of other medications you may be taking which can increase the risk of side effects. Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information for Important Safety Information.